TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33431619

Group type: EXPERIMENTAL
Intervention: Standardised echocardiographic approach
Number of subjects: 5998

Group type: COMPARATOR
Intervention: Traditional short-axis evaluation
Number of subjects: 5998

Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 5998

Group type: EXPERIMENTAL
Intervention: Conservative medical treatment
Number of subjects: 5998

Group type: EXPERIMENTAL
Intervention: Overall prevalence of AAOCA
Number of subjects: 5998

Group type: EXPERIMENTAL
Intervention: Symptoms of AAOCA
Number of subjects: 5998

Group type: EXPERIMENTAL
Intervention: Follow-up
Number of subjects: 5998
Study: 33431660

Group type: EXPERIMENTAL
Intervention: SIRP-1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SIRP-2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SIRP-1 and SIRP-2
Number of subjects: 0
Study: 33431814

Group type: EXPERIMENTAL
Intervention: High immune-ITH
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low immune-ITH
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immune-ITH
Number of subjects: 0
Study: 33431949

Group type: EXPERIMENTAL
Intervention: Proprioceptive stimuli in dyslexic children
Number of subjects: 34

Group type: COMPARATOR
Intervention: Proprioceptive stimuli in age-matched controls
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Proprioceptive acuity
Number of subjects: 34
Study: 33432540

Group type: EXPERIMENTAL
Intervention: Biosimilar etanercept 25 mg twice weekly or 50 mg once weekly
Number of subjects: 583

Group type: EXPERIMENTAL
Intervention: Biosimilar etanercept
Number of subjects: 583
Study: 33432547

Group type: EXPERIMENTAL
Intervention: SAR341402 insulin aspart (SAR-Asp)
Number of subjects: 597

Group type: COMPARATOR
Intervention: NN-Asp (NovoLog®/NovoRapid® insulin aspart)
Number of subjects: 597
Study: 33432705

Group type: EXPERIMENTAL
Intervention: miR-122
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: K18
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: DILI cases
Number of subjects: 235
Study: 33433145

Group type: EXPERIMENTAL
Intervention: Placebo treatment (42 patients)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Not treated (20 patients)
Number of subjects: 62
Study: 33433149

Group type: EXPERIMENTAL
Intervention: Maximal power cycling (PC) training for 8 weeks, 15 min per session, 3 times per week
Number of subjects: 39
Study: 33433155

Group type: EXPERIMENTAL
Intervention: Medium/high-risk genotype (HFE SNPs rs1800562 and rs1799945)
Number of subjects: 100
Study: 33433355

Group type: EXPERIMENTAL
Intervention: Halofuginone (HF) at 50 nM concentration
Number of subjects: 0

Group type: COMPARATOR
Intervention: TGF-β1 (pro-fibrotic agent)
Number of subjects: 0
Study: 33433485

Group type: EXPERIMENTAL
Intervention: Active-assisted mode
Number of subjects: 23

Group type: COMPARATOR
Intervention: Active mode
Number of subjects: 23
Study: 33433714

Group type: EXPERIMENTAL
Intervention: Psychosocial factors influencing consultation delay
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Logical model for change
Number of subjects: 14
Study: 33433743

Group type: EXPERIMENTAL
Intervention: Combination therapies involving immune checkpoint inhibitors (CTLA-4, PD-1, PD-L1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sipuleucel-T
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Future approaches involving bispecific antibodies and CAR-T cells
Number of subjects: 0
Study: 33433785

Group type: EXPERIMENTAL
Intervention: Topical Glycopyrronium Tosylate (GT) applied once daily for 5 days in phase I study; 0.8-3.2% GT applied once daily for 4 weeks in phase II studies.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical Glycopyrronium Tosylate (GT) applied once daily for 4 weeks in phase II studies.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral Glycopyrrolate administered every 8 hours for 15 days in phase I study.
Number of subjects: 0
Study: 33433896

Group type: EXPERIMENTAL
Intervention: GHD-CIM Observer-Reported Outcome (ObsRO) measure
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: GHD-CIM ObsRO measure
Number of subjects: 98
Study: 33434110

Group type: EXPERIMENTAL
Intervention: Automated anterior circulation CT angiographic clot detection platform
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (individuals without LVO)
Number of subjects: 0
Study: 33434161

Group type: EXPERIMENTAL
Intervention: rhIGF1 therapy
Number of subjects: 242
Study: 33434221

Group type: EXPERIMENTAL
Intervention: Corticosteroid immunomodulatory therapy
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: IP-10 measurements
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: IP-10 levels exceeding 1,000 pg/mL
Number of subjects: 52
Study: 33434290

Group type: EXPERIMENTAL
Intervention: Long-term bisphosphonate therapy in patients with atypical femur fracture (AFF)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Long-term bisphosphonate therapy in patients without atypical femur fracture (non-AFF)
Number of subjects: 52
Study: 33434314

Group type: EXPERIMENTAL
Intervention: 80 μg abaloparatide daily
Number of subjects: 23
Study: 33434453

Group type: EXPERIMENTAL
Intervention: Asynchronous Telepsychiatry Interviewer Training
Number of subjects: 0
Study: 33435412

Group type: EXPERIMENTAL
Intervention: Biomarker testing and treatment for TRK fusion cancer; specific details on dosage and duration not available.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified; details on control treatment not available.
Number of subjects: 0
Study: 33435695

Group type: EXPERIMENTAL
Intervention: %ddcfDNA measurement
Number of subjects: 171

Group type: COMPARATOR
Intervention: Control group (no rejection)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: %ddcfDNA monitoring
Number of subjects: 171
Study: 33435732

Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated devices
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nondrug-coated devices
Number of subjects: 0
Study: 33435865

Group type: EXPERIMENTAL
Intervention: Lower CD4 levels in COVID-19 patients
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: All-cause death
Number of subjects: 395
Study: 33435877

Group type: EXPERIMENTAL
Intervention: Technology-based obesity intervention
Number of subjects: 100
Study: 33435887

Group type: EXPERIMENTAL
Intervention: COVID-19 patients undergoing surgery
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: COVID-19 patients with symptoms
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: COVID-19 patients without symptoms
Number of subjects: 80

Group type: COMPARATOR
Intervention: Overall surgical activities during the pandemic
Number of subjects: 80
Study: 33435926

Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS)
Number of subjects: 100
Study: 33435974

Group type: EXPERIMENTAL
Intervention: Dynamic spectral imaging (DSI) color map directed biopsy
Number of subjects: 529

Group type: COMPARATOR
Intervention: All four cervical biopsies
Number of subjects: 529
Study: 33435973

Group type: EXPERIMENTAL
Intervention: Low-dose chest CT
Number of subjects: 165
Study: 33436007

Group type: EXPERIMENTAL
Intervention: NNI-362, an allosteric p70S6 kinase stimulator
Number of subjects: 0
Study: 33436012

Group type: EXPERIMENTAL
Intervention: Contemporary thrombosis prophylaxis
Number of subjects: 2208

Group type: EXPERIMENTAL
Intervention: Occurrence of PE-LDVT
Number of subjects: 2208

Group type: EXPERIMENTAL
Intervention: Occurrence of NLDVT
Number of subjects: 2208
Study: 33436021

Group type: EXPERIMENTAL
Intervention: Individual-based nutritional-lifestyle intervention
Number of subjects: 164

Group type: COMPARATOR
Intervention: Collective-based nutritional-lifestyle intervention
Number of subjects: 164
Study: 33436023

Group type: EXPERIMENTAL
Intervention: Geptanolimab 3 mg/kg intravenously every 2 weeks until disease progression or intolerable toxicity
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Geptanolimab in patients with PD-L1 expression ≥ 50%
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Geptanolimab in patients with PD-L1 expression < 50%
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Geptanolimab
Number of subjects: 102
Study: 33436025

Group type: EXPERIMENTAL
Intervention: Texting reporting method
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Calling reporting method
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Near-falls reporting
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Actual falls reporting
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Balance recovery manoeuvres
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Recruitment and retention
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Understanding of near-falls
Number of subjects: 30
Study: 33436090

Group type: EXPERIMENTAL
Intervention: 3-week behavioral change intervention
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 33436397

Group type: EXPERIMENTAL
Intervention: Multi-target stool DNA (mt-sDNA) test
Number of subjects: 816
Study: 33436455

Group type: EXPERIMENTAL
Intervention: Average annual medication costs per patient
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Ratio of medication to total health care costs
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Quality of prescribing
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Medication classes
Number of subjects: 4
Study: 33436493

Group type: EXPERIMENTAL
Intervention: Alteplase 20 mg and 10 mg (combined)
Number of subjects: 421

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 421
Study: 33436675

Group type: EXPERIMENTAL
Intervention: MTf-targeting antibody-drug conjugate (ADC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Murine unconjugated Fab fragment (SC57.32)
Number of subjects: 0
Study: 33436744

Group type: EXPERIMENTAL
Intervention: Solifenacin 5 mg taken once daily for three months
Number of subjects: 235
Study: 33436812

Group type: EXPERIMENTAL
Intervention: FGF 21 concentration in patients at ICU admission
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: FGF 21 concentration at 48 hours post-arrest
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Average FGF 21 concentration during the first 72 hours
Number of subjects: 112

Group type: COMPARATOR
Intervention: FGF 21 concentration in controls
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Neurological outcome assessment
Number of subjects: 112
Study: 33437832

Group type: EXPERIMENTAL
Intervention: Twice-daily IVR call reminders with self-management support messaging, plus a weekly IVR adherence assessment
Number of subjects: 362

Group type: COMPARATOR
Intervention: Attention control with only weekly IVR adherence assessment
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Twice-daily IVR call reminders
Number of subjects: 362

Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 362
Study: 33437997

Group type: EXPERIMENTAL
Intervention: Familial hypercholesterolaemia (FH)
Number of subjects: 5022

Group type: COMPARATOR
Intervention: Non-affected relatives (NAR)
Number of subjects: 5022
Study: 33438069

Group type: EXPERIMENTAL
Intervention: Bevacizumab (5-15 mg/kg) administered every 2 or 3 weeks, with or without chemotherapy
Number of subjects: 71
Study: 33438092

Group type: EXPERIMENTAL
Intervention: Maximal Expiratory Pressure (MEP) assessment before extubation after a successful spontaneous breathing trial.
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Maximal Inspiratory Pressure (MIP) was included in the multivariate model.
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Combination of MEP and MIP measurements.
Number of subjects: 124

Group type: COMPARATOR
Intervention: Not applicable (control group not specified).
Number of subjects: 124
Study: 33438438

Group type: EXPERIMENTAL
Intervention: Pulmonary transit time (PTT) from first-pass perfusion imaging
Number of subjects: 410

Group type: COMPARATOR
Intervention: Normal reference values of PTT in asymptomatic volunteers
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Clinical cMR parameters including LV and RV ejection fraction or feature tracking global longitudinal strain
Number of subjects: 410
Study: 33438477

Group type: EXPERIMENTAL
Intervention: Rezafungin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (other echinocandins)
Number of subjects: 0
Study: 33438658

Group type: EXPERIMENTAL
Intervention: Square wave
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Sinusoidal wavelet
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Both waveforms
Number of subjects: 9
Study: 33438862

Group type: EXPERIMENTAL
Intervention: Factors predictive of future relapse include age, intensity of craving, number of standard glasses consumed, psychiatric comorbidity (depression), employment and family/marital status.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Factors predictive of future relapse include consumption of other substances and greater intensity of craving at the time of alcohol withdrawal.
Number of subjects: 0
Study: 33439075

Group type: EXPERIMENTAL
Intervention: Decision Aid for Patients and Families
Number of subjects: 0
Study: 33439142

Group type: EXPERIMENTAL
Intervention: Personalized mobile phone app (My Braces)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 33439382

Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FLT3 inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Advanced risk stratification and new treatment strategies
Number of subjects: 0
Study: 33439463

Group type: EXPERIMENTAL
Intervention: MenACWY-DT vaccine
Number of subjects: 1311
Study: 33439583

Group type: EXPERIMENTAL
Intervention: Oral semaglutide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33439866

Group type: EXPERIMENTAL
Intervention: N-terminal prohormone of brain natriuretic peptide (NTproBNP)
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: high-sensitivity troponin T (cTnT-hs)
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: growth differentiation factor 15 (GDF-15)
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: transmembrane immunoglobulin and mucin domain protein (TIM-1)
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: renin
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: osteoprotegerin (OPG)
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: soluble suppression of tumorigenesis 2 protein (sST2)
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: cystatin-C (Cys-C)
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: tumor necrosis factor-related apoptosis-inducing ligand receptor 2 (TRAIL-R2)
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: carbohydrate antigen 125 (CA-125)
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: brain natriuretic peptide (BNP)
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: interleukin 6 (IL-6)
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: hepatocyte growth factor (HGF)
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: spondin-1
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: fibroblast growth factor 23 (FGF-23)
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: chitinase-3 like protein 1 (CHI3L1)
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: tumor necrosis factor receptor 1 (TNF-R1)
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: adrenomedullin (AM)
Number of subjects: 605
Study: 33440132

Group type: EXPERIMENTAL
Intervention: Inpatient stroke rehabilitation discharge (DC)
Number of subjects: 89
Study: 33440203

Group type: EXPERIMENTAL
Intervention: High levels of both irritability and ADHD symptoms
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: High levels of irritability and moderate levels of ADHD symptoms
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: Moderate levels of irritability and high levels of ADHD symptoms
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: Low levels of both irritability and ADHD symptoms
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: High overall irritability
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: Moderately comorbid ADHD symptoms
Number of subjects: 489
Study: 33441102

Group type: EXPERIMENTAL
Intervention: Cognitive impairment group (MMSE < 27)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Control group (MMSE ≥ 27)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Cognitive impairment measured using age- and education-adjusted MMSE scores
Number of subjects: 164
Study: 33441162

Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiation therapy (SABR)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Dynamic imaging biomarkers
Number of subjects: 26
Study: 33441362

Group type: COMPARATOR
Intervention: Severe haemophilia A and B without prophylaxis
Number of subjects: 240

Group type: COMPARATOR
Intervention: Mild, moderate, and severe haemophilia A or B with prophylaxis
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Patients with haemophilia A and B of comparable severity
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Patients with haemophilia
Number of subjects: 240
Study: 33441381

Group type: EXPERIMENTAL
Intervention: Amylase, lipase, and trypsinogen levels measured in patients with single-autoantibody positivity.
Number of subjects: 800
Study: 33441449

Group type: EXPERIMENTAL
Intervention: Viable genital CT load measured using V-PCR in women with genital CT (n=499)
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Women with urogenital symptoms
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Women with concurrent rectal CT
Number of subjects: 524
Study: 33441454

Group type: EXPERIMENTAL
Intervention: PPA-AD
Number of subjects: 31

Group type: COMPARATOR
Intervention: DAT-AD
Number of subjects: 31
Study: 33441669

Group type: EXPERIMENTAL
Intervention: 18% sodium substitute salt for 8 weeks
Number of subjects: 39
Study: 33442015

Group type: EXPERIMENTAL
Intervention: Cabozantinib
Number of subjects: 0
Study: 33442106

Group type: EXPERIMENTAL
Intervention: Insulin treatment
Number of subjects: 671
Study: 33442108

Group type: EXPERIMENTAL
Intervention: Prospective observation period (4 weeks)
Number of subjects: 2594

Group type: COMPARATOR
Intervention: Retrospective observation period (6 months)
Number of subjects: 2594
Study: 33442251

Group type: EXPERIMENTAL
Intervention: Once-every-3-months paliperidone palmitate (PP3M)
Number of subjects: 506
Study: 33442261

Group type: EXPERIMENTAL
Intervention: Theory-based self-management training program for peer leaders
Number of subjects: 0
Study: 33443137

Group type: EXPERIMENTAL
Intervention: Standard coiling
Number of subjects: 1135

Group type: EXPERIMENTAL
Intervention: Balloon-assisted coiling (BAC)
Number of subjects: 1135

Group type: EXPERIMENTAL
Intervention: Aneurysms <10 mm
Number of subjects: 1135

Group type: EXPERIMENTAL
Intervention: Aneurysms with narrow neck
Number of subjects: 1135

Group type: EXPERIMENTAL
Intervention: Patients aged <70 years
Number of subjects: 1135

Group type: EXPERIMENTAL
Intervention: Overall treatment (coiling or BAC)
Number of subjects: 1135
Study: 33443938

Group type: EXPERIMENTAL
Intervention: Synthetic mesh procedures
Number of subjects: 44594

Group type: EXPERIMENTAL
Intervention: Non-mesh procedures
Number of subjects: 44594

Group type: EXPERIMENTAL
Intervention: Transvaginal placement of surgical mesh (TVM) procedures
Number of subjects: 44594

Group type: EXPERIMENTAL
Intervention: Laparoscopic sacrocolpopexy (LSC) procedures
Number of subjects: 44594
Study: 33443981

Group type: EXPERIMENTAL
Intervention: In-person intervention
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Telephone intervention
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 100
Study: 33444080

Group type: EXPERIMENTAL
Intervention: CARG-BC score risk groups (low, intermediate, high) based on weighted predictors
Number of subjects: 473
Study: 33444177

Group type: EXPERIMENTAL
Intervention: New-onset diabetes mellitus (DM) screening program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MRI or endoscopic ultrasound investigation for patients with worrisome features
Number of subjects: 0
Study: 33444199

Group type: COMPARATOR
Intervention: Clinical surveillance with placebo (no anticoagulation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anticoagulant treatment with rivaroxaban
Number of subjects: 0
Study: 33444198

Group type: EXPERIMENTAL
Intervention: Personalised smoking cessation intervention (four individual counselling sessions over 12 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (one short counselling session at baseline and written information on smoking cessation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Personalised smoking cessation intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Personalised smoking cessation intervention (in a subsample of 80 participants)
Number of subjects: 0
Study: 33444268

Group type: EXPERIMENTAL
Intervention: CT-FFR
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: B-FFR-500
Number of subjects: 52
Study: 33444571

Group type: EXPERIMENTAL
Intervention: Community-Based Gastric Cancer Screening
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: National Colorectal Cancer Screening Program
Number of subjects: 0
Study: 33445053

Group type: EXPERIMENTAL
Intervention: Myeloid derived suppressor cells (MDSC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immunosuppressive tumor microenvironment (TME)
Number of subjects: 0
Study: 33445952

Group type: EXPERIMENTAL
Intervention: Mechanical deligation with intravenous recombinant tissue plasminogen activator administered 2 days after deligation
Number of subjects: 291

Group type: COMPARATOR
Intervention: Recombinant tissue plasminogen activator administered at day 4
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: PCDT in an intermediate symptom-onset-to-randomization timeframe of 4 to 8 days
Number of subjects: 291
Study: 33445991

Group type: EXPERIMENTAL
Intervention: HIPEC
Number of subjects: 21
Study: 33446112

Group type: EXPERIMENTAL
Intervention: Sideways walking intervention for 6 weeks
Number of subjects: 15
Study: 33446167

Group type: EXPERIMENTAL
Intervention: PT workshop intervention
Number of subjects: 208
Study: 33446655

Group type: EXPERIMENTAL
Intervention: NVX-CoV2373 vaccine with saponin-based Matrix-M adjuvant
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 33446895

Group type: EXPERIMENTAL
Intervention: Exposure and ritual prevention (EX/RP) therapy, 17 sessions, twice weekly
Number of subjects: 41